Top

BMC Infectious Diseases

Published in:

01-12-2021 | Nosocomial Infection | Research article

Pseudomonas aeruginosa device associated – healthcare associated infections and its multidrug resistance at intensive care unit of University Hospital: polish, 8.5-year, prospective, single-centre study

Authors: Agnieszka Litwin, Stanislaw Rojek, Waldemar Gozdzik, Wieslawa Duszynska

Published in: BMC Infectious Diseases | Issue 1/2021

Abstract

Background

Pseudomonas aeruginosa has recently shown to be one of the most important strains of bacteria and alert pathogens in Europe among Intensive Care Unit patients that provide serious therapeutic problems because of its multidrug resistance.

Methods

The purpose of this microbiological study was data analysis of device associated- healthcare associated infections (DA-HAIs) in an ICU in terms of the incidents of P.aeruginosa strain infections and its susceptibility within an 8.5-year observation.

Results

Among 919 isolated strains responsible for 799 DA-HAIs (17,62 ± 1,98/1000 patient-days) in 4010 ICU patients P.aeruginosa was the pathogen in 108/799 (13.52%) cases. Incidence rate (density) of: VAP/1000 MV- days, UTI /1000 UC- days and CLA-BSI/1000 CL- days were 11,15 ± 2.5, 6.82 ± 0.81, 2.35 ± 1.54.respectivelly. P.aeruginosa was the pathogen most frequently responsible for VAP 69/108 (63.88%). Mean frequency of VAP, UTI and CLA-BSI with P.aeruginosa etiology was 69/493 (14.28%), 32/299 (11.1%) and 7/127 (5.77%) respectively. The mean density of P.aeruginosa infection amounted to 2.43/1000 patient-days. The decrease was observed in the total number of DA-HAIs caused by the P.aeruginosa from 15.75% and 3.23/1000 patient-days in 2011 to 5.0% and 1.17/1000 in 2016 (p = 0.0104, p = 0.0348). Starting from 2016 to 2019 incidence and density of P.aeruginosa DA-HAIs increased to 12.33% and 2.63/1000 (p = 0.1388, p = 0.0818). P.aeruginosa was susceptible to ceftazidime, cefepime, amikacin, meropenem, ciprofloxacin, colistin, in 55.55, 58.33, 70.37, 53.73, 50, and 100% respectively. MDR characterised it in 40% in 2011 and 66.7% in 2019, (p = 0.177).

Conclusions

The study revealed a changeable prevalence of P. aeruginosa strain infections; however their frequency was never highest in our ICU patients as it presented in the last years in Europe. The study showed a significant decrease in 2016 and increase in 2019, a nearly 3-fold increase of P.aeruginosa infections among Gram-negative strain infections, and a 2-fold increase of the P.aeruginosa DA-HAIs frequency between 2016 and 2019 as well as an increased resistance. Microbiological analysis of DA-HAIs in each hospital should be a standard method used in hospital infection control and antibiotic policy. In the case of P.aeruginosa, in order to minimize transmission, preventive infection methods should be assessed mainly in case of VAP.

Alhazmi A. Pseudomonas aeruginosa – Pathogenesis and Pathogenic mechanism. Int J Biol. 2015;7:44–67. Available from. https://doi.org/10.5539/ijb.v7n2p44.CrossRef

Bassetti M, Vena A, Croxatto A, Righi E, Guery B. How to manage Pseudomonas aeruginosa infections. Drugs Context. 2018;7:212527. Avaliable from. https://doi.org/10.7573/dic.212527.CrossRefPubMedPubMedCentral

Moore NM, Flaws ML. Epidemiology and pathogenesis of Pseudomonas aeruginosa infection. Clin Lab Sci. 2011;24(1):43–6. Available from:. https://doi.org/10.29074/ascls24.1.43.CrossRefPubMed

European Centre for Disease Prevention and Control. Healthcare-associated infections acquired in intensive care units. In: ECDC Annual epidemiological report for 2016. Stockholm: ECDC; 2018. Available from https://www.ecdc.europa.eu/en/publications-data/healthcare-associated-infections-intensive-care-units-annual-epidemiological-0.

Ceniceros A, Peertega S, Galeiras R, et al. Predicting mortality in burn patients with bacteraemia. Infection. 2016;44(2):215–22. Available from. https://doi.org/10.1007/s15010-015-0847-x.CrossRefPubMed

European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe, Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net): ECDC; 2017. Available from: https://ecdc.europa.eu/sites/porta/files/documents/EARS-Net-report-2017-update-jan-2019.pdf

European Centre for Disease Prevention and Control. Healthcare-associated infections acquired in intensive care units. In: ECDC Annual epidemiological report for 2017. Stockholm: ECDC; 2019. Available from: https://www.ecdc.europa.eu/en/publications-data/healthcare-associated-infections-intensive-care-units-annual-epidemiological-1.

European Centre for Disease prevention and Control. Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals- protocol version 4.3. Stockholm: ECDC; 2012. Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/0512-TED-PPS-HAI-antimicrobial-use-protocol.pdf. Accessed 13 June 2017

European Centre for Disease Prevention and Control. European surveillance of healthcare associated infections in intensive care units-HAI-Net ICU protocol.version 1.02. Stockholm: ECDC; 2015. Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/health-care-associated-infections-HAI-ICU-protocol.pdf. Accessed 13 June 2017

10.

EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0 2016. Available from: http://www.eucast.org/clinical_breakpoints/ Accessed 1 Jan 2016.

11.

Magiorakos AP, Srinvisan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug–resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–81. Available from. https://doi.org/10.1111/j.1469-0691.2011.03570.x.CrossRefPubMed

12.

Duszynska W, Litwin A, Rojek S, Szczesny A, et al. Analysis of Acinetobacter baumannii hospital infections in patients treated at the intensive care unit of the University Hospital, Wroclaw, Poland: a 6-year, single-center, retrospective study. Infect Drug Resist. 2018;11:629–35. Available from. https://doi.org/10.2147/IDR.S162232.CrossRefPubMedPubMedCentral

13.

Rutkowska K, Przybyła M, Misiołek H. Health-care associated infection in the newly opened Intensive Care Unit. Anaesthesiol Intensive Ther. 2013;45(2):64–8. Available from. https://doi.org/10.5603/AIT.2013.0014.CrossRef

14.

Wieder-Huszla S. Monitoring of nosocomial infections in intensive care units. Ann Acad Med Stetin. 2010;56(3):20–9.PubMed

15.

Kołpa M, Wałaszek M, Gniadek A, Wolak Z, Dobroś W. Incidence, Microbiological Profile and Risk Factors of Healthcare-Associated Infections in Intensive Care Units: A 10 Year Observation in a district Hospital in Southern Poland. Int J Environ Res Public Health. 2018;15(1):112. Available from. https://doi.org/10.3390/ijerph15010112.CrossRefPubMedCentral

16.

Wałaszek M, Różańska A, Wałaszek MZ, Wójkowska-Mach, J Polish Society of Hospital Infections Team. Epidemiology of Ventilator-Associated Pneumonia, microbiological diagnostics and the length of antimicrobial treatment in the Polish Intensive Care Units in the years 2013–2015. BMC Infect Dis. 2018;18(1):308. Available from. https://doi.org/10.1186/s12879-018-3212-8.CrossRefPubMedPubMedCentral

17.

Duszynska W, Rosenthal VD, Dragan B, et al. Ventilator-associated pneumonia monitoring according to the INICC project at one centre. Anesthesiol Intensive Ther. 2015;47(1):34–9. Available from. https://doi.org/10.5603/AIT.2015.0004.CrossRef

18.

Moreira MR, Filho PG. Multidrug–resistant pathogens causing ventilator-associated pneumonia: risk factors, empirical antimicrobial therapy and outcome of patients in an intensive care unit (ICU) of Brazilian University hospital. Int J Med Sci. 2012;4(9):204–10.

19.

Dima S, Kritsotakis EI, Roumbelaki M, et al. Device-Associated Nosocomial Infection Rates in Intensive Care Units in Greece. Infect Control Hosp Epidemiol. 2007;28(5):602–5. Available from. https://doi.org/10.1086/513618.CrossRefPubMed

20.

Tomaszewski D, Rybicki Z, Duszynska W. The Polish Prevalence of Infection in Intensive Care (PPIC): A one–day point prevalence multicenter study. Adv Clin Exp Med. 2019;28(7):907–12 Available from. https://doi.org/10.17219/acem/94147.CrossRefPubMed

21.

Vincent J-L, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European prevalence of infection in intensive care (EPIC) study. EPIC international advisory committee. JAMA. 1995;274(8):639–44.CrossRefPubMed

22.

Vincent J-L, Sakr Y, Sprung CL, et al. Sepsis in European Intensive Care Units: results of the SOAP study. Crit Care Med. 2006;34(2):344–53. Available from. https://doi.org/10.1097/01.CCM.0000194725.48928.3A.CrossRefPubMed

23.

Vincent J-L, Rello J, Marshall J, et al. International study of prevalence and outcomes of infection in intensive care units. EPIC II. JAMA. 2009;302(21):2323–9. Available from. https://doi.org/10.1001/jama.2009.1754.CrossRefPubMed

24.

Vincent J-L, Sakr Y, Singer M, Martin-Loeches J, et al. Prevalence and Outcomes of Infection Among patients in Intensive Care Units in 2017. JAMA. 2020;323(15):1478–87. Available from. https://doi.org/10.1001/jama.2020.2717.CrossRefPubMedPubMedCentral

25.

Sakr Y, Jaschinski U, Wittebole X, ICON investigators, et al. Sepsis in intensive care unit patients: worldwide data from the intensive care over nations audit. Open Forum Infect Dis. 2018;5(12):ofy313. Available from. https://doi.org/10.1093/ofid/ofy313.CrossRefPubMedPubMedCentral

26.

Kubler A, Durek G, Zamirowska A, Duszynska W, et al. Severe sepsis in Poland –results of internet surveillance of 1043 cases. Med Sci Monit. 2004;10(11):CR635–41.PubMed

27.

Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention 2011–2014. Infect Control Hosp Epidemiol. 2016;37(11):1288–300. Available from. https://doi.org/10.1017/ice.2016.174.CrossRefPubMedPubMedCentral

28.

Rosenthal VD, Al-Abdely HM, El Kholy AA, et al. International nosocomial infection control consortium report, data summary of 50 countries for 2010-2015. Device –associated module. Am J Infect Control. 2016;44(12):1495–504. Available from:. https://doi.org/10.1016/j.ajic.2016.08.007.CrossRefPubMed

29.

Rosenthal VD, Bat-Erdene I, Gupta D, Belkebir S, et al. International nosocomial infection control consortium (INICC) report, data summary of 45 countries for 2012-2017. Device associated module. Am J Infect Control. 2020;48(4):423–32. Available from. https://doi.org/10.1016/j.ajic.2019.08.023.CrossRefPubMed

30.

Duszynska W, Rosenthal VD, Szczesny A, Zajaczkowska K, Fulek M, Tomaszewski J. Device associated-health care associated infections monitoring, prevention and cost assessment at intensive care unit of University Hospital in Poland (2015–2017). BMC Infect Dis. 2020;20:761 Available from. https://doi.org/10.1186/s12878-020-05482-w.CrossRefPubMedPubMedCentral

31.

Al-Mousa HH, Omar AA, Rosenthal VD, et al. Impact of the International Nosocomial Infection Control Consortium (INICC) multidimensional approach on rates of ventilator-associated pneumonia in intensive care units of two hospitals in Kuwait. J Infect Prev. 2018;19(4):168–76. Available from. https://doi.org/10.1177/2F1757177418759745.CrossRefPubMedPubMedCentral

32.

Pronovost P, Needhan D, Berenholtz S, Sinpoli D, et al. An Intervention to Decrease Catheter-Related Bloodstream Infections in the ICU. N Engl J Med. 2006;355:2725–32 Available from. https://doi.org/10.1056/NEJMoa061115.CrossRefPubMed

33.

Rosenthal VD, Pawar M, Leblebicioglu H, Navoa-Ng JA, et al. Impact of the international nosocomial infection control consortium (INICC) multidimensional hand hygiene approach over 13 years in 51 cities of 19 limited –resource countries from Latin America, Asia, the Middle East, and Europe. Infect Control Hosp Epidemiol. 2013;34(4):415–23 Available from https://www.jstor.org/stable/10.1086/669860.CrossRefPubMed

Title: Pseudomonas aeruginosa device associated – healthcare associated infections and its multidrug resistance at intensive care unit of University Hospital: polish, 8.5-year, prospective, single-centre study
Authors: Agnieszka Litwin
Stanislaw Rojek
Waldemar Gozdzik
Wieslawa Duszynska
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Nosocomial Infection
Care
Urinary Tract Infection
Pseudomonas Aeruginosa
Published in: BMC Infectious Diseases / Issue 1/2021
Electronic ISSN: 1471-2334
DOI: https://doi.org/10.1186/s12879-021-05883-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Culture positivity may correlate with long-term mortality in critically ill patients

Cytomegalovirus reactivation in immunocompetent mechanical ventilation patients: a prospective observational study

Two cases of multi-inflammatory syndrome in children (MIS-C) in adults in 2020

A multicentre interventional study to assess blood-borne viral infections in Belgian prisons

Malaria vector dynamics and utilization of insecticide-treated nets in low-transmission setting in Southwest Ethiopia: implications for residual transmission

Human papillomavirus genotypes and the risk factors associated with multicentric intraepithelial lesions of the lower genital tract: a retrospective study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials